Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSS0393 ointment in chronic plaque psoriasis
NCT06918743Phase 2Not yet recruiting
- Sponsor
- Hengrui
- Start
- Apr 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of RSS0393 in plaque psoriasis (3 arms), sponsored by Hengrui. Primary endpoint: Proportion of subjects with a clinician's overall assessment (PGA) response at 8 weeks. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
RSS0393
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06918743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06918743.